Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
PLN 25.9
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases using T-regulatory cells. It engages in the research and development of therapies for the treatment of type 1 diabetes in children and in multiple sclerosis. The company is based in Gdansk, Poland.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Data is available to registered users only
Target Price
The average target price of PTG.WA is 52 and suggests 100% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Data is available to registered users only
Buy
Sell